OrbiMed Advisors Buys $5.0M in Pre-Funded Warrants from Public Offering
STTK has more than doubled off its 52-week low of $0.712.
Summary
OrbiMed Advisors, an institutional investor with a board seat, purchased $5.0 million worth of pre-funded warrants in Shattuck Labs' recent public offering, signaling strong confidence.
Key Events · Ownership and Investor Activity · STTK
-
Significant Insider Purchase
OrbiMed Advisors, an institutional investor with a board representative, acquired 1,250,000 pre-funded warrants.
-
Value of Investment
The purchase totaled approximately $5.0 million, representing about 1.4% of Shattuck Labs' market capitalization.
-
Participation in Public Offering
The warrants were acquired on June 11, 2026, as part of the company's recently closed public offering, where warrants were priced at $3.9999 each.
-
Vote of Confidence
This substantial investment by a director-affiliated entity signals strong conviction in the company's outlook, especially following recent positive clinical trial data and a dilutive capital raise.
Analysis · STTK · Life Sciences
This Form 4 reports a significant investment by OrbiMed Advisors, an institutional investor with a board representative, in Shattuck Labs' recent public offering. The purchase of $5.0 million in pre-funded warrants at the offering price, representing about 1.4% of the company's market cap, indicates strong conviction following the company's positive Phase 1 clinical trial results and successful capital raise. This substantial insider participation provides a vote of confidence in the company's future prospects.
At the time of this filing, STTK was trading at $4.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $355M. The 52-week trading range was $0.71 to $8.33. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.